Oncotarget

Reviews:

Targeting Hsp90 in urothelial carcinoma

Mahmoud Chehab _, Tiffany Caza, Kamil Skotnicki, Steve Landas, Gennady Bratslavsky, Mehdi Mollapour and Dimitra Bourboulia

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:8454-8473. https://doi.org/10.18632/oncotarget.3502

Metrics: PDF 1955 views  |   HTML 1772 views  |   ?  


Abstract

Mahmoud Chehab1,*, Tiffany Caza2,*, Kamil Skotnicki1, Steve Landas1,2, Gennady Bratslavsky1,3, Mehdi Mollapour1,3,4, Dimitra Bourboulia1,3,4

1Department of Urology, SUNY Upstate Medical University, Syracuse, NY 13210, USA

2Department of Pathology, SUNY Upstate Medical University, Syracuse, NY 13210, USA

3Upstate Cancer Research Institute, SUNY Upstate Medical University, Syracuse, NY 13210, USA

4Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY 13210, USA

*These authors have contributed equally to this work

Correspondence to:

Dimitra Bourboulia, e-mail: bourmpod@upstate.edu

Keywords: urothelial carcinoma, pathogenesis, bladder cancer treatments, heat shock protein-90, Hsp90 inhibitors

Received: November 13, 2014     Accepted: March 09, 2015     Published: March 26, 2015

ABSTRACT

Urothelial carcinoma, or transitional cell carcinoma, is the most common urologic malignancy that carries significant morbidity, mortality, recurrence risk and associated health care costs. Despite use of current chemotherapies and immunotherapies, long-term remission in patients with muscle-invasive or metastatic disease remains low, and disease recurrence is common. The molecular chaperone Heat Shock Protein-90 (Hsp90) may offer an ideal treatment target, as it is a critical signaling hub in urothelial carcinoma pathogenesis and potentiates chemoradiation. Preclinical testing with Hsp90 inhibitors has demonstrated reduced proliferation, enhanced apoptosis and synergism with chemotherapies and radiation. Despite promising preclinical data, clinical trials utilizing Hsp90 inhibitors for other malignancies had modest efficacy. Therefore, we propose that Hsp90 inhibition would best serve as an adjuvant treatment in advanced muscle-invasive or metastatic bladder cancers to potentiate other therapies. An overview of bladder cancer biology, current treatments, molecular targeted therapies, and the role for Hsp90 inhibitors in the treatment of urothelial carcinoma is the focus of this review.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3502